Outcome of Board Meeting Held on 13th November, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma's board, which met on November 13, 2025, approved the unaudited financial results for the quarter and half-year ended September 30, 2025. Revenue from operations was nil for the quarter, with only ₹5.49 lakhs of other income, against ₹56.04 lakhs in the same quarter last year — a sharp ~90% drop. Profit after tax collapsed to just ₹1.38 lakhs (vs ₹48.40 lakhs YoY), and EPS fell to ₹0.01 from ₹0.82. The statutory auditor raised several red flags in its review report, including an Emphasis of Matter on funds raised through a preferential allotment where end-use could not be verified, inability to confirm whether certain transactions were related-party deals, and non-compliance with GST/TDS filing obligations where interest and penalties remain unprovided.
Serious concerns for shareholders — revenue from core operations has dried up entirely, profits have nearly vanished, and the auditor has flagged governance and statutory compliance issues without being able to verify key transactions. The stock is likely to see a negative reaction given the scale of the earnings drop and the auditor's reservations.